New cocktail of chemo and antibodies shows promise against aggressive stomach cancer
NCT ID NCT01191697
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested a combination of two chemotherapy drugs (capecitabine and oxaliplatin) plus two targeted antibodies (bevacizumab and trastuzumab) in 37 people with HER2-positive stomach or esophageal cancer that had spread. The goal was to see how safe and effective the combo was at shrinking tumors. Results showed that many patients had their tumors shrink, and the treatment helped control the disease for a time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- capecitabine, oxaliplatin, bevacizumab (Avastin), trastuzumab (Herceptin)
- What this could lead to
- If successful, this combination could offer a new treatment option that shrinks tumors and extends life for people with HER2-positive stomach or esophageal cancer that has spread.
- What could go wrong
- This is a small, early-phase trial with only 37 participants, so results may not apply to everyone. Combining multiple drugs also raises the risk of side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- Blood test score may flag High-Risk esophageal surgery patients
- Can surgery for stomach or esophageal cancer cloud the mind?